> **October 20, 2004**

**Curriculum Vitae**

Name: Michael Elliott Bigby

Office Address: Beth Israel Deaconess Medical Center

> Dermatology
>
> 330 Brookline Ave.
>
> Boston, MA 02215

Address: ........................................................

> .........
>
> ......................

E-Mail: mbigby@caregroup.harvard.edu

FAX: 617 667 4948

Place of Birth: ...................

Education:

> 1971 A.B. Princeton University, New Jersey
>
> 1975 M.D. Harvard Medical School, Boston, MA

Postdoctoral Training:

Internship and Residencies:

> 1975-1976 Intern in Medicine,
>
> Massachusetts General Hospital, Boston, MA
>
> 1976-1978 Resident in Medicine
>
> Massachusetts General Hospital, Boston, MA
>
> 1982-1984 Resident in Dermatology
>
> Department of Dermatology
>
> Harvard Medical School, Boston, MA
>
> 1984-1985 Chief Resident in Dermatology
>
> Department of Dermatology
>
> Harvard Medical School, Boston, MA

Research Fellowship:

1985-1988 Research Fellow in Immunology

> Department of Pathology
>
> Harvard Medical School, Boston, MA

Licensure and Certification:

> 1978-1990 Washington License Registration
>
> 1979 American Board of Internal Medicine, Certificate
>
> 1981- Massachusetts License Registration
>
> 1985 American Board of Dermatology, Certificate

Academic Appointments:

> 1979-1980 Clinical Instructor in Medicine
>
> University of Washington School of Medicine, Seattle, Washington
>
> 1980-1981 Clinical Assistant Professor of Medicine
>
> University of Washington School of Medicine, Seattle, Washington
>
> 1988-1991 Instructor in Dermatology
>
> Department of Dermatology, Harvard Medical School
>
> 1991- Assistant Professor of Dermatology
>
> Harvard Medical School, Boston, MA

Hospital Appointments or Affiliated Institution Appointments:

> 1978-1981 Internist
>
> U.S. Public Health Service Hospital, Seattle Washington
>
> 1981-1982 Internist
>
> Massachusetts General Hospital, Chelsea Health Center
>
> 1985- Active Staff
>
> Dept Dermatology, Beth Israel Deaconess Medical Center
>
> 1988-1991 Assistant in Pathology
>
> Massachusetts General Hospital, Boston, MA
>
> 1991-1996 Assistant in Dermatology
>
> Massachusetts General Hospital, Boston, MA
>
> 1998- Chief of Dermatology, Harvard University Health Service
>
> Other Professional Positions and Major Visiting Appointments:
>
> 1998 Visiting Professor Duke
>
> 1999 Visiting Professor University of Iowa

Major Administrative Responsibilities:

1998- Chief of Dermatology, Harvard University Health Service

Major Committee Assignments:

Medical School:

> 1987-1998 Residency Selection and Evaluation Committee
>
> Department of Dermatology, Harvard Medical School
>
> 1987-1988 Curriculum Committee
>
> Department of Dermatology, Harvard Medical School
>
> 1996- Council on Education
>
> Harvard Medical School-Beth Israel Deaconess
>
> Mount Auburn Institute for Education and Research
>
> 1999- Faculty Council
>
> Harvard Medical School

Hospital:

> 1988-1992 Pharmacy and Therapeutics Committee Beth Israel Hospital
>
> 1990-1994 Committee on Research, Massachusetts General Hospital
>
> 1994-1996 Subcommittee on Review of Research Proposals
>
> Massachusetts General Hospital

National:

> 1985-1995 Advisory Panel on Dermatology
>
> The United States Pharmacopoeia Convention
>
> 1985-1990, 1990-1995 Revision Cycles
>
> 1987-1989 Self-Assessment Committee
>
> American Academy of Dermatology
>
> 1995-1996 Merit Review Subcommittee on Immunology
>
> Department of Veterans Affairs
>
> 2000- Epidemiology Committee
>
> American Academy of Dermatology
>
> 2000- Chairman, Expert Committee on Dermatology
>
> The United States Pharmacopoeial Convention
>
> 2000-2005 Revision Cycle
>
> 2002- Quality of Care Task Force
>
> American Academy of Dermatology

Professional Societies:

> 1979-1982 American College of Physicians
>
> 1983-1985 Massachusetts Medical Society
>
> 1984- 1996 American Association for the Advancement of Science
>
> 1985- Society for Investigative Dermatology
>
> 1985- American Academy of Dermatology
>
> 1987- New England Dermatological Society
>
> 1987- Boston Dermatological Club
>
> 1987-1990 American Occupational Medical Association
>
> 1988-1990 American Federation for Clinical Research
>
> 1988-1992 Task force of Occupational and Environmental Dermatology,
> American Academy of Dermatology

Community Service Related to Professional Work

> 1990-1996 Science Fair Mentor
>
> MGH-Timilty Partnership Project, Massachusetts
>
> General Hospital
>
> 1990-1997 Board of Directors
>
> Lupus Foundation of America, Massachusetts Chapter.

Editorial Boards:

> 1985-1993 Book Review Editor
>
> Archives of Dermatology
>
> 1992- Editorial Board
>
> Archives of Dermatology
>
> 1995- Assistant Editor
>
> Journal of the American Academy of Dermatology
>
> 1999- Evidence-Based Dermatology section editor
>
> Archives of Dermatology
>
> 1999- Editor, Cochrane Skin Group, Cochrane Collaboration

Awards and Honors:

> 1971 Magna cum Laude in Chemistry, Princeton University
>
> 1971 Phi Beta Kappa
>
> 1971 Sigma Xi
>
> 1984-1988 Robert Wood Johnson Foundation
>
> Minority Medical Faculty Development Award
>
> 1985 Letter of Commendation, Dean Daniel Federman
>
> Teaching in Core Clinical Clerkship in Dermatology
>
> 1986 Eva Ljungwe Research Award
>
> Dermatology Foundation and Herbert Laboratories
>
> 1988 Avon Products Research Fellowship Award
>
> Dermatology Foundation and Avon Products, Inc.
>
> 2002 Service Award, Harvard University Health Service Research
>
> Teaching and Clinical Contributions:

A.  Narrative Report:

> Teaching: Evidence-based medicine

Dermatologists believe that clinical decisions can be made on the basis
of

understanding the pathophysiology of diseases, logic, trial and error,
and non-systematic observation. The most challenging issue facing the
specialty is to challenge this paradigm and to help dermatologists base
their practice on the best, currently available evidence. I have
contributed to bringing evidence-based medicine into the dermatology
lexicon especially in the US. This goal has been aided by publication of
an issue of the Archives of Dermatology devoted to evidence based
dermatology in December of 1998. (I was the special editor of this
issue), and the establishment of a quarterly section of the Archives
devoted to evidence based dermatology of which I am a substantially
contributing editor.

My contribution to educating dermatologists about evidence-based
medicine also include numerous invited lectures (e.g. many academic
institutions and the Philadelphia Dermatologic society), focus sessions
and forums at the annual meeting of the American Academy of Dermatology,
an opening session presentation at Academy 2000 (the annual summer
meeting of the American Academy of Dermatology) and publication of two
major review articles on evidence-based medicine in dermatology.

> Dermatology at Harvard Medical School

I have been heavily involved in teaching dermatology to Harvard medical
students for 17 years. In 1984 the medical school curriculum was revised
to require all of the 3rd year class to take a \"Core Clinical Clerkship
in Dermatology.\" The responsibility to develop the curriculum, arrange
the lectures and arrange and supervise patient viewing fell to me and
fellow chief resident, \-\-\-\-\-\-\-\-\--. The course taught the basics
of dermatologic diagnosis and therapy and was given to the entire class
in 1-month blocks. It was well received. For our efforts we received a
letter of Commendation from Dean Federman. I have been a lecturer and
small group leader in \" Pathophysiology of Skin\" (now part of Human
Systems Module I, IN708.0a) for 13 years and became co-director in 1996.
I helped develop the curriculum, organized lectures, and arranged small
group sessions. I developed the course web site with \-\-\-\-\-\-\--
(see <http://mycourses.med.harvard.edu/default.asp>). I am responsible
for almost all of the web content and a large portion of the written
content for the course. I also developed many of the techniques used to
make the small group sessions interactive and interesting for the
students. My evaluations for the lectures and small group sessions have
been consistently among the highest for the course. I am the primary
educator of Harvard Medical School dermatology residents on
evidence-based medical practice. I conduct a 2 or 3-session review of
evidence-based medicine principles for the dermatology residents at the
beginning of each academic year and then run a monthly evidence-based
medicine centered journal club in which the principles are used and
reinforced. Medical students doing the elective clinical rotation in
dermatology (DE501M.J) attend these sessions. My weekly student and
residency teaching clinical session is heavily devoted to evidence-based
practice and is recognized and appreciated for its practicality and
uniqueness. An abbreviated listing of the materials that I contribute to
IN708.0a or DE501M.J is identified by asterisk in the bibliography.
Computer assisted teaching in dermatology I developed a Dermatology
Teaching Module on CD to teach medical students an approach to
evaluating patients with skin disease. In the module, I interviewed,
examined and evaluated a patient with a lesion and a patient with a
rash. The module covers the performance and interpretation of office
diagnostic procedures and skin biopsy. There is also a patient for the
student to evaluate. The student\'s grasp of the principles of
dermatological history taking, physical examination and laboratory
testing is evaluated by a multiple-choice test. We are producing a
website that contains a quality database of dermatologic images and
text. A sophisticated, menu-driven search engine that utilizes keyword
and concept searching will run the site. It will generate a weighted
diagnosis or differential diagnosis based on input queries. The clinical
presentation (typical and variants) of the items in the differential
diagnosis will be available for viewing and brief summaries of the
disorders will be provided. Finally, the program will provide efficient
access to the best available information about management and things to
consider in deciding whether patients would benefit from a referral to a
dermatologist. Such a quick reference aid is becoming a necessity for
clinical teaching of medical students and as a resource for PCPs,
particularly for deciding whether a patient can be treated or needs to
be referred to a dermatologist.

> Clinical Contributions

I see patients at the Beth Israel Deaconess Medical Center privately and
in a resident teaching session. As the chief of dermatology at Harvard
University Health services I administer and provide patient care for an
outpatient dermatology service that has 6000 patient visits per year.
The department has 2 dermatologists, a dermatology nurse and 3 practice
assistants. We also provide educational and consultative service for
University Health Service primary care physicians and nurse
practitioners.

B.  Funding Information:

> 1/7/99-10/30/00 Dean's Clerkship Information Technology Innovation
> Fund,
>
> Harvard Medical School, Michael Bigby MD (PI), Abrar Quereshi MD
> (Co-PI).
>
> Virtual Dermatologist Web Site

C. Research Activities

Clinical Research/Evidence-based Medicine

Since entering dermatology, I have been interested in and have
investigated the clinical decision making process and the evidentiary
basis for decision making in dermatology. I did a cross sectional
analysis of method reporting and use in clinical trials in dermatology.
Finding that the methodology in dermatologic trials was generally poor
led me to write a comprehensive review article for dermatologists on
understanding and evaluating clinical trials. It also inspired me to
seek additional training in practicing and teaching evidence-based
medicine whose principles and practices I have introduced into
dermatology by writing comprehensive reviews, short reviews, research
commentaries, systematic reviews and a meta-analysis. I have also
investigated the rates of cutaneous reactions to drugs based on the
Boston Collaborative Drug Surveillance Program data, performed a
systematic review of published studies reporting rates of reactions to
drugs, and developed profiles of adverse reactions to non-steroidal
anti-inflammatory drugs and to isotretinoin. Role of T cells in normal
skin and inflammatory skin diseases I did research centered on
understanding the immunobiology of inflammatory skin diseases. We
established T lymphocyte clones and keratinocyte lines from the same
biopsy specimens of LP patients. Several of the clones have lytic
activity against autologous lesional keratinocytes. We tested the
hypothesis that CD8+ T cells that are cytotoxic towards autologous
keratinocytes are involved in the pathogenesis of LP and that they can
be cloned from lesional skin from LP patients and be used to identify
autoantigens present in lesional keratinocytes. We developed an *in
vitro* system for comparing dermal and epidermal T cell migration and
adhesion to autologous keratinocytes cultured from the same human skin
biopsy specimen. Lymphocyte migration and adhesion to autologous
immortalized keratinocytes was assessed in calcein fluorimetric assays.
Epidermal lymphocyte migrated towards autologous keratinocytes four
times more than dermal lymphocytes. Epidermal lymphocytes adhere to
autologous keratinocytes two to four times more than dermal lymphocytes.
These data support the hypothesis that both directed migration
(epidermotropism) and selective retention may be involved in the
development of the epidermal T cell population.

> Role of Ikaros in Lymphopoiesis

While I was in the Cutaneous Biology Research Center, my laboratory
formed a close alliance with .............................. to study the
role of Ikaros in lymphocyte development and homeostasis. Mice
homozygous for a mutation that deletes sequences that encode part of the
DNA binding domain of Ikaros proteins (DB -/-) exhibit a very early
arrest in lymphocyte development. A second line of mice with a mutation
that deletes sequences that encode the C-terminal domain of the Ikaros
proteins (C-/-) have variable numbers of αβ T cells but lack B cells and
their earliest progenitors. γδ T cells and NK cells were absent or
significantly reduced in these mice. Mice heterozygous for the
C-terminal mutation appear healthy and phenotypically normal. We
assessed the phenotypic and functional consequences of normal and
mutated Ikaros expression.

D. Teaching:

1\. Local Contributions:

> a\. Harvard Medical School Courses:
>
> 1984-1985 Core Clinical Clerkship in Dermatology (Co-organizer, with
> Dr. Howard Koh). Entire third year class. Developed curriculum,
> organized lectures, and arranged patient viewing.
>
> 1988-1995 Pathophysiology of Skin (Lecturer and Small Group Leader).
> Second year class. Developed 1996- Pathophysiology of Skin (now part
> of Human Systems Module I) (Co-Director). Second year class. Developed
> curriculum, organized lectures, arranged small group sessions,
> developed course web site, lectured and led small group session.
>
> 1997-1998 Dermatology Teaching Module for Virtual Patient Project
> (Developer) all classes. Developed a Multimedia Teaching Module in
> Dermatology to teach students basics of history taking, physical
> examination and office procedures in evaluating patients with skin
> disease.
>
> b\. Graduate Medical Courses/Seminars/Invited Teaching Presentations:
>
> 1985- Beth Israel Deaconess Medical Center, Dermatology Seminars.
> Codirector. Twelve to 15 dermatology residents. Monthly, 1-hour
> session for the full year devoted to teaching evidence-based medicine
> in dermatology.
>
> 1985-1998 Beth Israel Deaconess Medical Center, Dermatology Seminars.
> Monthly, 1-hour session for a half year devoted to teaching basic
> science.
>
> 1985-1992 Occupational Skin Diseases (Lecturer). Harvard School of
> Public Health. Graduate students of Occupational Health
>
> c\. Continuing Medical Education Courses:
>
> 1995- Practical Dermatology for the Non-dermatologist (Lecturer), HMS
> CME.
>
> d\. Advisory and Supervisory Responsibilities in Clinical or
> Laboratory Setting:
>
> 1985- Attending Physician, Dermatology, resident teaching session,
> Beth
>
> Israel Deaconess Medical Center-East Campus. Eight residents, 12 to
>
> 20 medical students and 12 medical residents per year. One half day
> per
>
> week each year.
>
> e\. Leadership Roles:
>
> 1996- Co-Director. Pathophysiology of Skin (now part of Human Systems
>
> Module I). Developed curriculum, organized lectures, arranged small
>
> group sessions, developed course web site, lectured and led small
> group
>
> session.
>
> 2002 Scholar, the Academy at Harvard Medical School

2\. Regional, National or International Contributions:

> 1 Invited Presentations
>
> American Academy of Dermatology Annual Meeting. Focus session
> director.
>
> Symposium lecturer.
>
> Lecture "Evidence-based Medicine, Quinsigamond Dermatological Society,
>
> University of Massachusetts.
>
> Lecture "Evidence-based Medicine, Dermatology Teacher Exchange Group
>
> Visiting Professor, Duke University Medical School, Department of
>
> Dermatology
>
> Visiting Professor, University of Iowa, Department of Dermatology.
>
> Lecture, Emerging Trends in Dermatology, Association of Professors of
>
> Dermatology
>
> Opening Session "Dermatology Dilemmas in the New Millennium," Academy
>
> 2000, American Academy of Dermatology
>
> Pommerening Memorial Lecture, Washington State Dermatology Association
>
> and Visiting Professor, Department of Dermatology University of
> Washington
>
> Visiting Professor, Department of Dermatology, Emory University,
> School of
>
> Medicine, Atlanta, GA
>
> Clinical Activities:
>
> 1978-1981 Attending Physician, Medicine, U.S. Public Health Service
> Hospital,
>
> Seattle, Washington
>
> 1979-1981 Emergency Room Director, U.S. Public Health Service Hospital
>
> Seattle, Washington
>
> 1985- Active Staff Dept of Dermatology and Attending Physician,
>
> Dermatology, Beth Israel Deaconess Medical Center

**Bibliography**

Original Reports:

1\. Stern RS, Bigby M. An expanded profile of cutaneous reactions to
nonsteroidal anti-inflammatory drugs: Reports to a specialty-based
system for spontaneous reporting of

adverse reactions to drugs. JAMA 1984;252:1433-37.

2\. Bigby M, Stern RS. Cutaneous reactions to nonsteroidal
anti-inflammatory drugs. J

Am Acad Dermatol 1985;12:866-76.

3\. Bigby M, Stern RS, Bigby J. An evaluation of method reporting and
use in clinical

trials in dermatology. Arch Dermatol 1985;121:1394-99.

4\. Bigby M, Jick S, Jick H, Arndt KA. Drug induced cutaneous reactions:
A report from

the Boston Collaborative Drug Surveillance Program on 15,791 Consecutive

Inpatients. 1975-82. JAMA 1986;256:3358-63.

5\. Bigby M, Kwan T, Sy M-S. The ratio of Langerhans cells to Thy-1+
dendritic

epidermal cells in murine epidermis influences the intensity of contact

hypersensitivity. J Invest Dermatol 1987;89:495-99.

6\. Wang PTH, Bigby M, Sy M-S. Selective down modulation of L3T4
molecules on

murine thymocytes by the tumor promoter, phorbol 12-myristate 13
acetate. J

Immunol 1987;139:2157-65.

7\. Bigby M, Stern RS. Adverse reactions to isotretinoin: a report from
the adverse drug

reaction reporting system. J Am Acad Dermatol 1988;18:543-52.

8\. Sleckman BP, Bigby, M, Greenstein JL, Burakoff SJ, Sy MS,
Requirements for

Modulation of the CD4 Molecule in Response to PMA: Role of the
Cytoplasmic

Domain. J. Immunol 1989;142:1457-62.

9\. Bigby M, Vargas R, Sy M-S. Production of antigen specific T-cell
hybridomas and

their use to study the effects of UVB irradiation on the development of
contact

hypersensitivity. J. Immunol 1989;143:3867-72.

10\. Bigby M, Wang P, Fierro JF, Sy M-S. Phorbol-myristate-acetate
induced down

modulation of CD4 is dependent on calmodulin and intracellular calcium.
J Immunol

1990;144:3111-16.

11\. Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria:
clinical efficacy of

citirizine in comparison with hydroxyzine and placebo. J Allergy Clin
Immunol

1990;86:1014-18.

12\. Phillips TJ, Bigby M, Bercovitch L. Cultured allografts as an
adjunct to the medical

treatment of problematic leg ulcers. Arch Dermatol 1991;127:799-801.

13\. Dunn DA, Gadenne A-S, Simha S, Lerner EA, Bigby M, Bleicher PA.
T-cell

receptor Vβ expression in normal human skin. Proc Natl Acad Sci USA
1993;90:1257-

71\.

14\. Bigby M, Markowitz JS, Bleicher PA, Grusby MJ, Simha S, Siebrecht
M, Wagner M,

Nagler-Anderson C, Glimcher LH. Most γδ T cells develop normally in the
absence of

MHC class II molecules. J Immunol 1993;151:4465-75.

15\. Guo Y-J, Ma J, Wang J-H, Lin S-C, Chang, H-C, Bigby M, Sy M-S.
Monoclonal anti-

CD44 antibody acts in synergy with anti-CD2 but inhibits anti-CD3 or T
cell receptor

mediated signaling in murine T cell hybridomas. Cellular Immunol
1993;152:186-99.

16\. Guo Y-J, Lin S-C, Wang J-H, Bigby M, and Sy M-S. Palmitoylation of
CD44

interferes with CD3-mediated signaling in human T lymphocytes.
International

Immunology 1994;6:213-21.

17\. Guo Y, Ma J, Wang J-H, Che X, Narula J, Bigby M, Wu M and Sy M-S.
Inhibition of

human melanoma growth and metastasis *in Vivo* by anti-CD44 monoclonal
antibody.

Cancer Research 1994;54:1561-65.

18\. Ma J, Wang J-H, Sy M-S, Guo Y-J, Hauser C, Bigby M. Trinitrophenol
reactive T-cell

hybridomas recognize antigens that require antigen processing. J Invest
Dermatol,

1994;103:42-48.

19\. Gadenne, A-S, Strucke, R, Dunn, D, Wagner, M, Bleicher, P and
Bigby, M.

T-Cell Lines Derived from Lesional Skin of Lichen Planus Patients
Contain a

Distinctive Population of T Cell Receptor γδ Bearing Cells. J Invest
Dermatol,

1994;103:347-51

20 Ma J, Wang J-H, Guo Y-J, Sy M-S and Bigby M. *In Vivo* Treatment with
Anti-ICAM-

1 and Anti-LFA-1 Antibodies Inhibits Contact Sensitization Induced
Migration of

Epidermal Langerhans Cells to Regional Lymph Nodes. Cellular Immunol,
1994,

158:389-99.

21 Georgopoulos K, Bigby M, Wang J-H, Molnar A, Wu P, Winandy S and
Sharpe A.

The Ikaros gene is required for the development of all lymphoid
lineages. Cell, 1994,

79:143-56.

22 Wang J-H, Nichogiannopoulou A, Wu l, Sun L, Sharpe A, Bigby M and
Georgopoulos

K. Selective defects in the development of the fetal and adult lymphoid
system in mice

with an Ikaros null mutation. Immunity, 1996;5:537-549.

23 Sugerman PB, Bigby M. Preliminary functional analysis of human
epidermal T cells.

Arch Derm Res 2000; 292: 9-15.

24 Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse
transcriptasepolymerase

chain reaction for tyrosinase mRNA as a marker for circulating tumor

cells in cutaneous melanoma. Arch Dermatol. 2001 Mar;137(3):325-30.

25 Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001
Jun;137(6):765-

70\.

26 Bigby M, Gibbs S, Harvey I, Sterling J. Skin disorders/Non-genital
warts. In *Clinical*

*Evidence* Issue 7 2002:1530-42.

Clinical Communications:

1\. Bigby M, McKoy K. Acrocyanosis with atrophy. Arch Dermatol
1988;124:263-68.

2\. Baden L, Bigby M, Kwan T. Persistent necrotic digits in a patient
with the acquired

immunodeficiency syndrome. Herpes simplex virus infection. Arch Dermatol

1990;127:113,116.

Reviews and Educationally Relevant Publications:

Comprehensive review article in refereed journal:

1\. Bigby M, Stern RS, Arndt KA. Allergic cutaneous reactions to drugs.
Prim Care. 1989

Sep;16(3):713-27.

2\. Bigby M, Gadenne A-S. Understanding and evaluating clinical trials.
J Am Acad

Dermatol 1996, 34:555-583.

3\. Bigby M. Evidence-based medicine in a nutshell: finding and using
the best evidence

in caring for patients. Arch Dermatol 1998, 134:1609-17.

4\. Bigby M. Evidence-based medicine in dermatology. Dermatologic
Clinics. 2000 in

press.

5\. Sugerman PB, Savage NW, Zhou X, Walsh LJ, Bigby M. Oral lichen
planus. Clin

Dermatol. 2000 Sep-Oct;18(5):533-9. Review.

6\. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, Seymour
GJ,

Bigby M. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med

2002;13:350-65.

Analytic clinical reviews, clinical observations, educational studies in
refereed journals:

1\. Bigby M, Arndt KA. Contempo 1985 - Dermatology. JAMA
1985;254:2283-86.

2\. Bigby M, Arndt KA. Contempo 1986 - Dermatology. JAMA
1986;256:2084-86.

3\. Bigby M. Transdermal Clonidine Dermatitis. JAMA 1987;258:1819.

4\. Bigby M. Dermatitis and the risk of HIV infection. JAMA
1988;259:3184-85.

5\. Bigby M. Nonsteroidal anti-inflammatory drug reactions. In Seminars
in dermatology,

Shear NH, Maibach HI (eds).1989 pp. 182-186.

6\. Bigby M. Everyone wants to go to heaven, but nobody wants to die. Am
J

Dermatopathol 1994;16:329-31.

7\. Bigby M. Ruling out the diagnosis. Editorial. Arch Dermatol
1996;132:697-8.

8\. Bigby M. Call for papers: evidence-based medicine. Arch Dermatol,
1998,. 134:227.

9\. Bigby M. Snake oil for the 21st century. Arch Dermatol, 1998,
134:1512-13.

10\. Bigby M. Welcome to evidence-based medicine. Arch Dermatol 1998,
134:1516-17.

11\. Bigby M. Welcome to the "evidence-based dermatology" section in the
. Archives of

Dermatology. Arch Dermatol 1999, 135:1512.

12\. Abeni D, Bigby M, Pasquini P, Szklo M, Williams H. "Evidence-based
dermatology"

section in the . Archives of Dermatology purpose and procedure. Arch
Dermatol 1999,

135:1512-1513.

13\. Bigby M. The sunscreen and melanoma controversy. Arch Dermatol
1999, 135:1526-

1527\.

14\. Bigby M. Paradigm Lost. Arch Dermatol 2000; 136:26-27.

15\. Bigby M. Confidence intervals. Arch Dermatol 2000;:
Mar;136(3):386-7.

16\. Bigby M. A Systematic review of the treatment of scabies. Arch
Dermatol 2000;

Mar;136(3):387-9.

17\. Bigby M. Odds Ratios and Relative Risks. Arch Dermatol 2000,
Jun;136(6):770-1.

18\. Bigby M.A Remarkable Result of a Double-Masked, Placebo-Controlled
Trial of

Erythromycin the Treatment of Pityriasis Rosea. Arch Dermatol. 2000
Jun;136(6):775-

776\.

19\. Liu V, Bigby M.. Reactivation of genital herpes simplex virus 2
infection in

asymptomatic seropositive persons is frequent. Arch Dermatol. 2000
136:1141-2.

20\. Chartier T, Bigby M. Rational follow-up recommendations for
patients with

melanoma. Arch Dermatol. 2000 Sep;136(9):1145-7.

21\. Bigby M. Sunscreens, nevi, and melanoma revisited. Arch Dermatol.
2000

Dec;136(12):1549-50.

22\. Bigby M. Challenges to the hierarchy of evidence: does the emperor
have no clothes?

Arch Dermatol. 2001 Mar;137(3):345-6.

23\. Bigby M. A population-based estimate of the prevalence of
post-herpetic neuralgia

after herpes zoster. Arch Dermatol. 2001 Jun;137(6):789-90.

24\. Bigby M. Incidence, prevalence and the rates of cutaneous reactions
to drugs. J Eur

Acad Dermatol Venereol. 2000 Nov;14(6):435.

25\. Bigby M. A thorough systematic review of treatments for atopic
eczema. Arch

Dermatol. 2001 Dec;137(12):1635-6.

26\. Bigby M. The placebo effect: and another one bites the dust. Arch
Dermatol. 2001

Dec;137(12):1639-40.

27\. Albrecht J, Bigby M. The meaning of \"Safe and Effective.\" J Am
Acad Dermatol 2003

48:144-7.

Text Books

1\. Olbricht S, Bigby M, Arndt K, eds.. *Manual of Clinical Problems in
Dermatology*.

Boston: Little, Brown and Company, 1992.

2\. Williams HC, Bigby M, Diepgen T, Herxheimer A, Naldi L and Rzany B.
Evidence-

Based Dermatology. London:BMJ Books (in press).

Chapters in Books:

1\. Arndt K, Bigby M. Skin Disorders. In: Levy BS, Wegman DH, eds.,
*Occupational*

*Health*. Boston, MA, Little, Brown and Company, 1988:371-85.

2\. Bigby M, Stern RS, Arndt KA. Allergic cutaneous reactions to drugs.
In: Pariser RJ,

ed., *Primary Care*, W.B. Saunders, 1989:713-27.

3\. Bigby M, Arndt KA. Prevention of occupational skin diseases. In:
Wagner G, Levy B,

Weeks J, eds. *Preventing Occupational Disease and Injury*., *American
Public Health*

*Association*, Boston, MA, 1991.

4\. Bigby M. Nonsteroidal antiinflammatory drugs: uses in dermatology
and cutaneous

toxicity. In: Lewis, Fyrst, eds. *Nonsteroidal Anti-inflammatory Drugs:
Mechanisms*

*and Clinical Uses, Second Edition*, Marcel Dekker, Inc., 1993:207-16.

5\. Coopman S, Bigby M, Arndt K. Skin Disorders. In: Levy BS, Wegman DH,
eds.

*Occupational Health*, Little, Brown and Company, 1994:491-506.

6\. White C, Bigby M, Sanqueza O. What is normal skin? anatomy,
regional, age, and

racial differences in skin. In: Arndt KA, LeBoit P, Robinson J, Wintrob
B, eds.

*Cutaneous Medicine and Surgery*, W.B. Saunders Company, 1995:3-45.

7\. Gadenne A-S, Bigby M, Camisa C. Lichen planus and related disorders.
In: Arndt KA,

LeBoit P, Robinson J, Wintrob B, eds. *Cutaneous Medicine and Surgery*,
W.B.

Saunders Company, 1995:235-243.

8\. Bigby M. Dermatology. In Armitage P and Colton T, eds. *Encyclopedia
of*

*Biostatistics*, John Wiley & Sons Ltd.

9\. Bigby ME, Arndt KA and Coopman SA. Skin Disorders In: Levy BS,
Wegman DH,

eds. *Occupational Health*, 4th ed Lippincot Williams & Wilkins,
1999:537-552.

10\.
..................................................................................................................................................................................................................................................................................(in
press).

Books and Monographs (other than text books)

Bigby M, David AK, Brown AE. Recognition and Management of Skin Diseases
in

People of Color. Glaxo Inc. Medical and Professional Education, 1996.

Non-Print Materials

1\. Bigby M. Nonsteroidal anti-inflammatory drugs. Dialogues in
Dermatology

1987;20:#4.

2\. Bigby M. Evidence based medicine. Dialogues in Dermatology July,
1999.

3\. Bigby M, Qureshi A. Virtual dermatology patients (CD) 2001.